Korean Stock Flows

Onconic Therapeutics (KRX: 476060)

온코닉테라퓨틱스 KOSDAQ Biotech & Pharma 자연과학 및 공학 연구개발업
Close (Oct 13, 2026)
₩13,710
-3.59%
Market cap
₩1T ($0.5B)
52-week range
₩8,790 – ₩28,900
P/E (FY1 fwd) · P/B · Div yield
20.55 · 8.47 · 0%
trailing 38.19 · consensus of analysts

Who is buying Onconic Therapeutics?

Between Sep 10, 2026 and Oct 13, 2026 (20 trading sessions), foreign investors net bought ₩2.2bn ($2M) of Onconic Therapeutics, the 113th largest foreign net purchase among 1828 KOSDAQ stocks. Institutions net sold ₩1.1bn ($1M) and retail investors net sold ₩1.3bn ($1M) over the same window. Foreigners were net buyers on 10 of the 20 sessions.

Foreign investors hold 0.21% of Onconic Therapeutics' listed shares (KRX ownership data as of Oct 13, 2026), up from 0% twenty sessions earlier and 9.51% a year ago.

The stock closed at ₩13,710 on Oct 13, 2026: -14.79% over 20 sessions, -29.87% year-to-date, -36.97% over one year. The 52-week range is ₩8,790 – ₩28,900.

At ₩13,710 the stock trades at 20.55× current-fiscal-year consensus earnings. The trailing P/E published by KRX is 38.19×, based on the last completed fiscal year.

Onconic Therapeutics share price, last 60 trading days (KRW)
18,541 15,360 12,180 8,999 Jul 13 Aug 26 Oct 13
Daily foreign investor net purchases, last 60 trading days
+10.5bn +5.2bn -5.2bn -10.5bn Jul 13 Aug 26 Oct 13
View chart data as a table
Date Close Foreign net Institutions Retail
2026-10-13 ₩13,710 +₩0.5bn +₩0.0bn ₩-0.5bn
2026-10-12 ₩14,220 +₩0.2bn +₩0.0bn ₩-0.2bn
2026-10-08 ₩14,870 ₩-0.4bn ₩-0.0bn +₩0.6bn
2026-10-07 ₩15,510 ₩-0.9bn ₩-0.0bn +₩0.9bn
2026-10-06 ₩15,600 ₩-0.2bn +₩0.0bn +₩0.1bn
2026-10-02 ₩15,710 ₩-1.4bn +₩0.0bn +₩1.5bn
2026-10-01 ₩15,920 +₩3.0bn +₩0.0bn ₩-2.9bn
2026-09-30 ₩15,350 +₩0.6bn +₩0.1bn ₩-0.7bn
2026-09-29 ₩15,330 ₩-2.2bn ₩-0.1bn +₩1.8bn
2026-09-28 ₩15,980 +₩1.4bn +₩0.1bn ₩-1.3bn
2026-09-23 ₩15,130 ₩-0.5bn ₩-0.0bn +₩0.5bn
2026-09-22 ₩14,730 ₩-0.5bn ₩-0.2bn +₩0.7bn
2026-09-21 ₩15,050 +₩0.8bn ₩-0.0bn ₩-0.8bn
2026-09-18 ₩14,860 ₩-0.3bn +₩0.0bn +₩0.2bn
2026-09-17 ₩15,120 +₩1.3bn ₩-0.0bn ₩-1.3bn
2026-09-16 ₩14,600 +₩0.0bn +₩0.0bn ₩-0.1bn
2026-09-15 ₩14,700 ₩-0.0bn ₩-0.5bn +₩0.4bn
2026-09-14 ₩14,630 +₩0.7bn ₩-0.2bn ₩-0.5bn
2026-09-11 ₩14,950 +₩0.8bn ₩-0.3bn ₩-0.5bn
2026-09-10 ₩15,620 ₩-0.7bn +₩0.0bn +₩0.6bn
2026-09-09 ₩16,090 +₩0.7bn +₩0.0bn ₩-0.7bn
2026-09-08 ₩16,050 ₩-0.2bn ₩-0.0bn +₩0.2bn
2026-09-07 ₩16,290 +₩0.0bn ₩-0.0bn ₩-0.0bn
2026-09-04 ₩16,440 ₩-0.8bn +₩0.0bn +₩0.8bn
2026-09-03 ₩17,110 ₩-0.6bn +₩0.0bn +₩0.7bn
2026-09-02 ₩16,800 ₩-1.2bn ₩-0.0bn +₩0.9bn
2026-09-01 ₩17,990 ₩-1.9bn ₩-0.0bn +₩1.9bn
2026-08-31 ₩18,030 +₩0.6bn ₩-0.0bn ₩-0.4bn
2026-08-28 ₩14,770 +₩1.5bn +₩0.0bn ₩-1.5bn
2026-08-27 ₩14,370 +₩0.1bn +₩0.1bn ₩-0.1bn
2026-08-26 ₩14,460 ₩-0.3bn ₩0.0bn +₩0.0bn
2026-08-25 ₩14,370 ₩-0.0bn +₩0.1bn +₩0.1bn
2026-08-24 ₩14,520 ₩-0.2bn ₩-0.1bn +₩0.4bn
2026-08-21 ₩14,520 ₩-1.5bn +₩0.2bn +₩1.6bn
2026-08-20 ₩14,730 +₩0.4bn ₩-0.5bn ₩-0.1bn
2026-08-19 ₩14,000 +₩0.8bn ₩-0.4bn ₩-0.5bn
2026-08-18 ₩14,250 +₩0.4bn ₩-0.0bn ₩-0.2bn
2026-08-14 ₩14,810 ₩-0.8bn ₩-0.3bn +₩1.0bn
2026-08-13 ₩15,480 ₩-1.0bn +₩0.0bn +₩0.6bn
2026-08-12 ₩15,800 +₩0.7bn +₩0.3bn ₩-0.9bn
2026-08-11 ₩14,850 ₩-3.2bn ₩-0.0bn +₩3.2bn
2026-08-10 ₩14,670 ₩-0.6bn ₩-0.1bn +₩0.6bn
2026-08-07 ₩14,050 ₩-1.0bn ₩-0.8bn +₩1.3bn
2026-08-06 ₩15,940 ₩-5.5bn +₩1.4bn +₩4.4bn
2026-08-05 ₩13,030 +₩1.2bn ₩-0.0bn ₩-1.2bn
2026-08-04 ₩12,650 ₩-1.6bn ₩-0.0bn +₩1.2bn
2026-08-03 ₩11,240 ₩-0.2bn +₩0.0bn +₩0.1bn
2026-07-31 ₩10,820 +₩1.2bn +₩0.1bn ₩-1.3bn
2026-07-30 ₩9,510 +₩1.4bn +₩0.0bn ₩-1.4bn
2026-07-29 ₩9,520 +₩0.7bn ₩-0.0bn ₩-0.7bn
2026-07-28 ₩10,310 +₩0.0bn +₩0.0bn ₩-0.0bn
2026-07-27 ₩11,090 +₩0.5bn +₩0.0bn ₩-0.5bn
2026-07-24 ₩10,940 ₩-0.2bn ₩-0.0bn +₩0.2bn
2026-07-23 ₩11,550 +₩2.0bn ₩0.0bn ₩-2.0bn
2026-07-22 ₩10,960 +₩1.0bn ₩-0.0bn ₩-1.0bn
2026-07-21 ₩11,500 ₩-0.5bn ₩-1.3bn +₩1.8bn
2026-07-20 ₩13,240 ₩-2.3bn ₩-0.1bn +₩2.4bn
2026-07-16 ₩14,500 ₩-10.5bn +₩0.0bn +₩10.5bn
2026-07-15 ₩12,050 ₩-2.2bn +₩1.2bn +₩1.1bn
2026-07-14 ₩10,720 +₩0.2bn ₩-0.0bn ₩-0.1bn
2026-07-13 ₩10,920 ₩-0.5bn +₩0.0bn +₩0.5bn

Investor flows summary

Window Foreign (USD) Institutions Retail
1 day +₩0.5bn +$0M +₩0.0bn ₩-0.5bn
5 days ₩-0.7bn $-1M +₩0.0bn +₩0.9bn
20 days +₩2.2bn +$2M ₩-1.1bn ₩-1.3bn

Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.

Frequently asked questions

Are foreign investors buying Onconic Therapeutics stock?

Over the last 5 sessions foreign investors net sold ₩0.7bn ($1M) of Onconic Therapeutics; over 60 sessions they net sold ₩20.7bn ($16M); since Jan 1, 2026 they net sold ₩14.7bn ($11M). Over 20 sessions the stock is the 113th largest foreign net purchase among 1828 KOSDAQ stocks.

How much of Onconic Therapeutics do foreign investors own?

Foreign investors own 0.21% of Onconic Therapeutics' shares as of Oct 13, 2026, versus 9.51% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.

Who is on the other side — institutions or retail investors?

Over 20 sessions institutions net sold ₩1.1bn ($1M) and retail investors net sold ₩1.3bn ($1M) of Onconic Therapeutics. Foreign buying is being met mainly by retail selling.

Is Onconic Therapeutics listed on KOSPI or KOSDAQ?

Onconic Therapeutics (온코닉테라퓨틱스) trades on KOSDAQ under KRX code 476060 in the Biotech & Pharma group, with a market capitalization of ₩1T ($0.5B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.

Annual financials

Fiscal year Revenue YoY Operating profit Net income
2024 – – -₩5bn (-$4M) -₩8bn (-$6M)
2025 – – ₩13bn ($9M) ₩16bn ($12M)

Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1333.09/$) for reference only.

← All foreign investor flows